8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 29, 2026·SEC
Citius Pharmaceuticals, Inc.(CTXR)Earnings, Financials & Key Ratios
CTXR•NASDAQ
$0.61
Price updated Jul 6, 2026
AboutCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.Show more
- Revenue$0
- EBITDA-$38M+8.3%
- Net Income-$37M+4.4%
- EPS (Diluted)-3.38+43.4%
- ROE-49.38%-4.4%
CTXR Price & Volume
Citius Pharmaceuticals, Inc. (CTXR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Deficits Threaten Clinical Pipeline Viability
Investment Thesis • Updated 2026Q2
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Citius Pharmaceuticals faces a precarious outlook as it struggles to transition from a clinical-stage entity to a commercial operation, evidenced by a deepening retained earnings deficit of $268.3M.
- The firm's reliance on stock-based compensation, which reached $4.3M in 2026Q1, highlights a strategy of cash preservation that simultaneously dilutes shareholder value.
- Investors should remain cautious given the company's inability to generate consistent revenue and the significant liquidity risks posed by a current ratio that has deteriorated to 0.58 as of 2026Q2.
Verdict Logic
Negative: The company's current ratio of 0.58 and the accumulation of $268.3M in retained earnings deficits suggest an imminent risk of insolvency or further dilutive financing that outweighs potential clinical upside.
CTXR Growth Metrics
Citius Pharmaceuticals, Inc. (CTXR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM3498.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.99%
Return on Capital
10 Years-49.62%
5 Years-36.38%
3 Years-42.87%
Last Year-46.18%
CTXR Recent Earnings
Citius Pharmaceuticals, Inc. (CTXR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.95-344.5%
$0.39
Rev
$2M-91.1%
$19M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.38-188.4%
$0.43
Rev
$4M-78.1%
$18M
Q4 2025
Dec 25, 2025Metric
Actual
Est
EPS
$0.44-83.5%
$0.24
Rev
$4M
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.80-233.3%
$0.24
Rev
—
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.95vs $0.39-344.5% | $2Mvs $19M-91.1% |
| Q1 2026 | Feb 13, 2026 | $0.38vs $0.43-188.4% | $4Mvs $18M-78.1% |
| Q4 2025 | Dec 25, 2025 | $0.44vs $0.24-83.5% | $4M |
| Q3 2025 | Aug 12, 2025 | $0.80vs $0.24-233.3% | —vs $2M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Citius Pharmaceuticals, Inc. (CTXR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.61 | $6.79M | -0.18 | — | — | -49.38% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $34.13 | $1.38B | 28.68 | 27.37% | 6.35% | 29.49% | — | |
| $38.02 | $1.04B | -223.65 | 104.94% | -1.7% | -5.68% | — |
Compare CTXR vs Peers
Citius Pharmaceuticals, Inc. (CTXR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTXR SEC Filings & Documents
Citius Pharmaceuticals, Inc. (CTXR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CTXR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTXR Frequently Asked Questions
Citius Pharmaceuticals, Inc. (CTXR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Citius Pharmaceuticals, Inc.'s revenue?
Citius Pharmaceuticals, Inc. (CTXR) reported $5.6M in revenue for fiscal year 2025.
Is CTXR profitable?
Citius Pharmaceuticals, Inc. (CTXR) reported a net loss of $46.2M for fiscal year 2025.
Dividend & Returns
What is CTXR's return on equity?
Citius Pharmaceuticals, Inc. (CTXR) has a return on equity (ROE) of -49.4%. Negative ROE indicates the company is unprofitable.
What is Citius Pharmaceuticals, Inc.'s free cash flow?
Citius Pharmaceuticals, Inc. (CTXR) had negative free cash flow of $31.6M in fiscal year 2025, likely due to heavy capital investments.